Summary of Patient Characteristics, Treatment Protocol, Remission Status, and Adverse Events
| Parameter | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|---|---|---|---|---|---|---|
| Baseline characteristics | ||||||
| Sex | Male | Female | Male | Male | Female | Female |
| Age (y) | 52 | 58 | 83 | 73 | 75 | 39 |
| Meningioma WHO grade | III | II | II | II | II | I |
| First diagnosed (mo before inclusion) | 20 | 89 | 192 | 60 | 60 | 96 |
| Previous therapy | ||||||
| Last surgical treatment (mo before inclusion) | 8 | 64 | 31 | 7 | 59 | 83 |
| Last radiation therapy (mo before inclusion) | 16 | ND | 13 | 54 | 55 | 54 |
| Last systemic treatment (mo before inclusion) | 1 | ND | ND | ND | ND | ND |
| Treatment protocol | ||||||
| [177Lu]Lu-DOTATOC therapy | ||||||
| Number of cycles | 1 | 1 | 1 | 1 | 1 | 1 |
| Total injected activity (GBq) | 7.1 | 7.1 | 6.9 | 7.3 | 7.3 | 7.0 |
| [177Lu]Lu-DOTA-JR11 therapy | ||||||
| Injected activity at first cycle (GBq) | 4.5 | 4.9 | 3.3 | 4.0 | 4.1 | 3.7 |
| Number of cycles | 2 | 2 | 2 | 3 | 3 | 2 |
| Total injected activity (GBq) | 9.0 | 8.9 | 7.4 | 11.6 | 10.4 | 7.1 |
| Remission status* | ||||||
| Remission status before inclusion | PD | PD | PD | PD | PD | PD |
| Progression interval before inclusion (mo) | 4 | 27 | 27 | 4 | 23 | 5 |
| Meningioma volume change before inclusion (%) | +8,280 | +45 | +88 | +50 | +40 | +61 |
| Remission status after maximum follow-up | PD | SD | SD | SD | SD | SD |
| Additional treatments after inclusion† | Yes | Yes | No | No | No | No |
| Maximum follow-up after inclusion (mo) | 15 | 22 | 16 | 15 | 17 | 12 |
| Meningioma volume change at maximum follow-up (%) | +778 | +9 | +31 | +19 | 0 | −3 |
| Adverse events (grade) | ||||||
| Up to 10 wk after [177Lu]Lu-DOTATOC | ||||||
| Anemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutropenia | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphopenia | 0 | 2 | 0 | 0 | 1 | 2 |
| Thrombocytopenia | 0 | 0 | 0 | 0 | 0 | 0 |
| Up to 10 wk after first cycle of [177Lu]Lu-DOTA-JR11 | ||||||
| Anemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutropenia | 0 | 0 | 0 | 0 | 3 | 0 |
| Lymphopenia | 0 | 2 | 0 | 0 | 2 | 3 |
| Thrombocytopenia | 0 | 0 | 0 | 0 | 0 | 0 |
| Up to 13 mo after first cycle of [177Lu]Lu-DOTA-JR11 | ||||||
| Anemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutropenia | 0 | 0 | 0 | 0 | 0 | 2 |
| Lymphopenia | 0 | 3 | 0 | 0 | 3 | 3 |
| Thrombocytopenia | 0 | 0 | 0 | 0 | 0 | 0 |
↵* Remission status of meningiomas assessed with MRI volumetry.
↵† Patient 1 received high-dose chemotherapy with ifosamid 7 mo after termination of [177Lu]Lu-DOTA-JR11 therapy followed by therapy with mitogen-activated extracellular signal-regulated kinase inhibitor (cobimetinib). Patient 2 was treated with humanized monoclonal antibody (bevacizumab) 6 mo after termination of [-Lu]Lu-DOTA-JR11 therapy.
ND = not done; PD = progressive disease; SD = stable disease.